In addition, targeting the NLRP3 inflammasome (e.g., MCC950 [200]) or downstream IL1β (e.g., Canakinumab [87,200]) has raised concerns over increased susceptibility to pathogenic infection and long-term side effects. Here, NLRP3 is linked to infection.